Home LiteratureArticle Details
PMID: 23785431 Published · epublish English Journal Article Research Support, Non-U.S. Gov't

S100P expression is a novel prognostic factor in hepatocellular carcinoma and predicts survival in patients with high tumor stage or early recurrent tumors.

PloS one ·Vol. 8 ·No. 6 ·2013-00-00 ·Pages e65501

Yuan RH, Chang KT, Chen YL, Hsu HC, Lee PH, Lai PL, Jeng YM

Abstract

The calcium-binding protein S100P is expressed in a variety of human cancer cells and is important in cancer cell growth and invasion. Using differential display, we found S100P is overexpressed in human hepatocellular carcinoma (HCC). We examined the expression of 305 unifocal, primary HCC tumors using immunohistochemistry. The S100P protein was expressed in 173 of the 305 (56.7%) HCC tumors. The expression of S100P correlated with female sex (P = 0.0162), high serum α-fetoprotein level (P = 0.0001), high tumor grade (P = 0.0029), high tumor stage (P = 0.0319), the presence of the p53 mutation (P = 0.0032), and the absence of the β-catenin mutation (P = 0.0489). Patients with HCC tumors that expressed S100P were more likely to have early tumor recurrence (ETR) (P = 0.0189) and lower 5-year survival (P = 0.0023). The multivariate analysis confirmed that S100P expression was an independent prognostic factor in HCC. The combinatorial analysis showed an additive unfavorable prognostic interaction between S100P expression and the p53 mutation. In contrast, the β-catenin mutation was associated with better prognosis in both S100P-positive and -negative HCCs. Furthermore, S100P expression was a predictor of survival in HCC patients with high tumor stage or ETR (P = 0.0026 and P = 0.0002, respectively). Our study indicates the expression of the S100P protein is a novel independent predictor for poor prognosis in HCC, and it is also an unfavorable prognostic predictor in HCC patients with high tumor stage or ETR.

MeSH Terms
Adult Aged Calcium-Binding Proteins/genetics,metabolism Carcinoma, Hepatocellular/genetics,mortality,pathology Female Gene Expression Humans Liver/metabolism Liver Neoplasms/genetics,mortality,pathology Male Middle Aged Mutation Neoplasm Proteins/genetics,metabolism Neoplasm Staging Prognosis Recurrence Tumor Burden Tumor Suppressor Protein p53/genetics,metabolism beta Catenin/genetics,metabolism
Chemicals
Calcium-Binding Proteins Neoplasm Proteins S100P protein, human Tumor Suppressor Protein p53 beta Catenin
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Yuan Ray-Hwang
Department of Surgery, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan.
Chang Ko-Tung
Chen Yu-Ling
Hsu Hey-Chi
Lee Po-Huang
Lai Po-Lin
Jeng Yung-Ming
References (50)
50 references, click to expand
  1. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma.
    J Pathol. 2006 Aug;209(4):549-58 PMID: 16739096
  2. Hepatocellular carcinoma: diagnosis and treatment.
    Gastroenterology. 2002 May;122(6):1609-19 PMID: 12016426
  3. Pathologies involving the S100 proteins and RAGE.
    Subcell Biochem. 2007;45:93-138 PMID: 18193636
  4. Genetic alterations at the splice junction of p53 gene in human hepatocellular carcinoma.
    Hepatology. 1994 Jan;19(1):122-8 PMID: 7903951
  5. Calcium-binding protein S100P and cancer: mechanisms and clinical relevance.
    J Cancer Res Clin Oncol. 2012 Jan;138(1):1-9 PMID: 21947242
  6. Ca2+-dependent binding and activation of dormant ezrin by dimeric S100P.
    Mol Biol Cell. 2003 Jun;14(6):2372-84 PMID: 12808036
  7. Targeted disruption of S100P suppresses tumor cell growth by down-regulation of cyclin D1 and CDK2 in human hepatocellular carcinoma.
    Int J Oncol. 2009 Dec;35(6):1257-64 PMID: 19885547
  8. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution.
    Cancer Res. 1997 Nov 15;57(22):5179-84 PMID: 9371521
  9. Unfavourable prognostic significance of S100P expression in ovarian cancers.
    Histopathology. 2007 Jul;51(1):125-8 PMID: 17539915
  10. S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE).
    J Biol Chem. 2004 Feb 13;279(7):5059-65 PMID: 14617629
  11. CacyBP/SIP, a calcyclin and Siah-1-interacting protein, binds EF-hand proteins of the S100 family.
    J Biol Chem. 2002 Aug 9;277(32):28848-52 PMID: 12042313
  12. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations.
    Int J Cancer. 2004 Oct 20;112(1):44-50 PMID: 15305374
  13. Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent.
    J Pathol. 2003 Sep;201(1):63-74 PMID: 12950018
  14. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma.
    Cancer. 2003 Jul 1;98(1):119-27 PMID: 12833464
  15. Opposite roles of human pancreatitis-associated protein and REG1A expression in hepatocellular carcinoma: association of pancreatitis-associated protein expression with low-stage hepatocellular carcinoma, beta-catenin mutation, and favorable prognosis.
    Clin Cancer Res. 2005 Apr 1;11(7):2568-75 PMID: 15814635
  16. Aberrant expression of the glycolytic enzymes aldolase B and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis.
    Oncol Rep. 2008 Apr;19(4):1045-53 PMID: 18357395
  17. S100P expression in human esophageal epithelial cells: Human esophageal epithelial cells sequentially produce different S100 proteins in the process of differentiation.
    Anat Rec. 2002 May 1;267(1):60-9 PMID: 11984793
  18. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis.
    Am J Pathol. 2000 Sep;157(3):763-70 PMID: 10980116
  19. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.
    Cancer. 1954 May;7(3):462-503 PMID: 13160935
  20. Identification of hypermethylated genes associated with cisplatin resistance in human cancers.
    Cancer Res. 2010 Apr 1;70(7):2870-9 PMID: 20215521
  21. S100P, a potential novel prognostic marker in colorectal cancer.
    Oncol Rep. 2012 Jul;28(1):303-10 PMID: 22552710
  22. Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma.
    Eur J Cancer. 2007 Mar;43(4):736-44 PMID: 17267202
  23. Functional evidence implicating S100P in prostate cancer progression.
    Int J Cancer. 2008 Jul 15;123(2):330-339 PMID: 18452169
  24. Mutations of p53 gene in hepatocellular-carcinoma (hcc) correlate with tumor progression and patient prognosis - a study of 138 patients with unifocal hcc.
    Int J Oncol. 1994 Jun;4(6):1341-7 PMID: 21567059
  25. S100P dissociates myosin IIA filaments and focal adhesion sites to reduce cell adhesion and enhance cell migration.
    J Biol Chem. 2012 May 4;287(19):15330-44 PMID: 22399300
  26. Hepatocellular carcinoma.
    Lancet. 1999 Apr 10;353(9160):1253-7 PMID: 10217098
  27. S100P, a novel Ca(2+)-binding protein from human placenta. cDNA cloning, recombinant protein expression and Ca2+ binding properties.
    Eur J Biochem. 1992 Jul 15;207(2):541-7 PMID: 1633809
  28. S100P calcium-binding protein overexpression is associated with immortalization of human breast epithelial cells in vitro and early stages of breast cancer development in vivo.
    Int J Oncol. 2000 Feb;16(2):231-40 PMID: 10639564
  29. Overexpression of KIAA0101 predicts high stage, early tumor recurrence, and poor prognosis of hepatocellular carcinoma.
    Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5368-76 PMID: 17875765
  30. S100 protein translocation in response to extracellular S100 is mediated by receptor for advanced glycation endproducts in human endothelial cells.
    Biochem Biophys Res Commun. 2004 Apr 9;316(3):949-59 PMID: 15033494
  31. S100P is an early developmental marker of pancreatic carcinogenesis.
    Clin Cancer Res. 2006 Sep 15;12(18):5411-6 PMID: 17000674
  32. Induction of metastasis by S100P in a rat mammary model and its association with poor survival of breast cancer patients.
    Cancer Res. 2006 Jan 15;66(2):1199-207 PMID: 16424059
  33. Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration.
    Breast Cancer Res. 2012 Mar 14;14(2):R45 PMID: 22417809
  34. Expression of p53 gene in 184 unifocal hepatocellular carcinomas: association with tumor growth and invasiveness.
    Cancer Res. 1993 Oct 1;53(19):4691-4 PMID: 8402647
  35. S100P immunostaining identifies a subset of peripheral-type intrahepatic cholangiocarcinomas with morphological and molecular features similar to those of perihilar and extrahepatic cholangiocarcinomas.
    Histopathology. 2012 Dec;61(6):1106-16 PMID: 22882148
  36. Different roles of S100P overexpression in intrahepatic cholangiocarcinoma: carcinogenesis of perihilar type and aggressive behavior of peripheral type.
    Am J Surg Pathol. 2011 Apr;35(4):590-8 PMID: 21412073
  37. The induction of S100p expression by the Prostaglandin E₂ (PGE₂)/EP4 receptor signaling pathway in colon cancer cells.
    Cancer Biol Ther. 2010 Nov 15;10(10):1056-66 PMID: 20890108
  38. Role of p53 and β-catenin mutations in conjunction with CK19 expression on early tumor recurrence and prognosis of hepatocellular carcinoma.
    J Gastrointest Surg. 2011 Feb;15(2):321-9 PMID: 21061181
  39. RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways.
    Dis Colon Rectum. 2007 Aug;50(8):1230-40 PMID: 17587138
  40. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis.
    Gastroenterology. 2001 Jun;120(7):1763-73 PMID: 11375957
  41. Role of L2DTL, cell cycle-regulated nuclear and centrosome protein, in aggressive hepatocellular carcinoma.
    Cell Cycle. 2006 Nov;5(22):2676-87 PMID: 17106265
  42. S100A2-S100P expression profile and diagnosis of non-small cell lung carcinoma: impairment by advanced tumour stages and neoadjuvant chemotherapy.
    Eur J Cancer. 2007 Sep;43(13):1935-43 PMID: 17689067
  43. S100P promotes pancreatic cancer growth, survival, and invasion.
    Clin Cancer Res. 2005 Aug 1;11(15):5356-64 PMID: 16061848
  44. Cloning and expression of CD24 gene in human hepatocellular carcinoma: a potential early tumor marker gene correlates with p53 mutation and tumor differentiation.
    Cancer Res. 1995 Oct 15;55(20):4717-21 PMID: 7553654
  45. Calcium-binding protein S100P is a novel diagnostic marker of cholangiocarcinoma.
    Cancer Sci. 2011 Jan;102(1):150-6 PMID: 21029254
  46. S100P calcium-binding protein expression is associated with high-risk proliferative lesions of the breast.
    Oncol Rep. 2006 Jan;15(1):3-6 PMID: 16328027
  47. Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer.
    Am J Pathol. 2005 Jan;166(1):81-92 PMID: 15632002
  48. The calcium-binding protein S100P in normal and malignant human tissues.
    BMC Clin Pathol. 2008 Feb 18;8:2 PMID: 18282279
  49. Smooth muscle actin and s100p on non germinal centre diffuse large B cell lymphoma are adverse prognostic factors: pilot study.
    Diagn Pathol. 2007 Mar 02;2:9 PMID: 17335572
  50. Characterization of the Ca2+ -regulated ezrin-S100P interaction and its role in tumor cell migration.
    J Biol Chem. 2008 Oct 24;283(43):29331-40 PMID: 18725408
Article Info
Journal
PloS one
Abbr.
PLoS One
ISSN
1932-6203
DOI
10.1371/journal.pone.0065501
Published
2013-00-00
Epub
2013-00-13
Pages
e65501
Language
English
Region
United States
NLM ID
101285081
PMCID
PMC3681902
Subset
IM
External Links
PubMed source DOI: 10.1371/journal.pone.0065501 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2